الفهرس 
Multiple myeloma
Our study included 2 groups (60 patients and 20 control )Only 14 pages are availabe for public view
 |  | from | 165 |  |  |
| | | from | 165 | | |
Abstract
Multiple myeloma is a clonal proliferation of malignant plasma cells within the bone marrow, results in over-production of monoclonal protein (M-protein) and causes organ and system damage, which results in anaemia, hypercalcemia, renal dysfunction and lytic bone disease. Interleukin 10 is an inflammatory cytokine which is secreted mainly by myeloma-associated macrophages and has an important role in proliferation and differentiation of B cells into plasma cells and progression of the disease. Neutrophil–lymphocyte ratio and red blood cell distribution width have diagnostic and prognostic value in both haematological and non haematological malignancies. The aim of our work was to evaluate the prognostic role of red cell distribution width, neutrophil lymphocyte ratio and interleukin 10 in multiple myeloma patients. The study was carried out on: group 1: 60 Patients with newly diagnosed multiple myeloma, they were subdivided according to the international staging system into three subgroups: Stage I: 10 patients. Stage II: 17 patients. Stage III: 33 patients. group 2: 20 apparently healthy subjects as control group. All the study groups were subjected to: Full history taking. Full clinical examination. Laboratory investigations include:C. Routine lab tests: Urine analysis. Complete blood count with estimation of RDW and NLR. Blood urea and serum creatinine. Serum albumin. Serum calcium. Erythrocyte sedimentation rate (ESR). Serum lactate dehydrogenase (LDH). D. Special lab tests: Serum protein electrophoresis (for patient only). Bone marrow aspiration and biopsy (for patient only). Immunofixation (for patient only). Serum β-2 microglobulin. Serum interleukin 10 estimation. Our result showed the following: Non significant difference between the studied groups regarding to age and sex (P>0.05). Significant increase in IL 10, RDW, NLR, β2M, Creatinine, total calcium, ESR and LDH in disease stages in comparison to control (P< 0.001). Significant decrease in Hb and albumin in disease stages in comparison to control (P< 0.001). Non significant difference between disease stages regarding to M protein (P> 0.05). Significant difference between disease stages regarding to Plasma cells (P< 0.05).